A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 1,027,617 shares of NTLA stock, worth $12.4 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares
1,027,617
Previous 769,917 33.47%
Holding current value
$12.4 Million
Previous $17.2 Million 22.56%
% of portfolio
0.05%
Previous 0.04%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$19.72 - $27.36 $5.08 Million - $7.05 Million
257,700 Added 33.47%
1,027,617 $21.1 Million
Q2 2024

Aug 14, 2024

BUY
$20.02 - $27.22 $2.21 Million - $3.01 Million
110,600 Added 16.77%
769,917 $17.2 Million
Q1 2024

May 15, 2024

BUY
$23.82 - $32.8 $4.65 Million - $6.41 Million
195,300 Added 42.09%
659,317 $18.1 Million
Q4 2023

Feb 14, 2024

BUY
$23.16 - $32.34 $4.87 Million - $6.8 Million
210,400 Added 82.96%
464,017 $14.1 Million
Q3 2023

Nov 14, 2023

SELL
$31.62 - $45.78 $777,852 - $1.13 Million
-24,600 Reduced 8.84%
253,617 $8.02 Million
Q2 2023

Aug 14, 2023

SELL
$34.58 - $46.03 $8.91 Million - $11.9 Million
-257,700 Reduced 48.09%
278,217 $11.3 Million
Q1 2023

May 15, 2023

SELL
$33.3 - $44.82 $1.54 Million - $2.08 Million
-46,300 Reduced 7.95%
535,917 $20 Million
Q4 2022

Feb 14, 2023

SELL
$33.21 - $62.69 $56,457 - $106,573
-1,700 Reduced 0.29%
582,217 $20.3 Million
Q3 2022

Nov 14, 2022

SELL
$53.92 - $71.7 $7.08 Million - $9.41 Million
-131,300 Reduced 18.36%
583,917 $32.7 Million
Q2 2022

Aug 15, 2022

BUY
$38.49 - $76.21 $10.7 Million - $21.1 Million
277,200 Added 63.29%
715,217 $37 Million
Q1 2022

May 16, 2022

BUY
$58.27 - $118.99 $9.75 Million - $19.9 Million
167,300 Added 61.8%
438,017 $31.8 Million
Q4 2021

Feb 14, 2022

BUY
$100.76 - $138.36 $10.2 Million - $13.9 Million
100,800 Added 59.32%
270,717 $32 Million
Q3 2021

Nov 15, 2021

SELL
$132.37 - $176.78 $31.8 Million - $42.5 Million
-240,300 Reduced 58.58%
169,917 $22.8 Million
Q2 2021

Aug 16, 2021

SELL
$60.88 - $161.91 $16.4 Million - $43.6 Million
-269,500 Reduced 39.65%
410,217 $66.4 Million
Q1 2021

May 17, 2021

BUY
$46.59 - $83.68 $6.49 Million - $11.6 Million
139,200 Added 25.75%
679,717 $54.6 Million
Q4 2020

Feb 16, 2021

BUY
$18.83 - $63.53 $1.58 Million - $5.33 Million
83,900 Added 18.37%
540,517 $29.4 Million
Q3 2020

Nov 16, 2020

BUY
$17.47 - $24.93 $2.22 Million - $3.17 Million
127,300 Added 38.66%
456,617 $9.08 Million
Q2 2020

Aug 14, 2020

BUY
$11.14 - $22.87 $806,536 - $1.66 Million
72,400 Added 28.18%
329,317 $6.92 Million
Q1 2020

May 15, 2020

BUY
$9.44 - $15.58 $236,000 - $389,500
25,000 Added 10.78%
256,917 $3.14 Million
Q4 2019

Feb 14, 2020

BUY
$10.43 - $17.67 $975,205 - $1.65 Million
93,500 Added 67.55%
231,917 $3.4 Million
Q3 2019

Nov 14, 2019

BUY
$13.07 - $18.51 $533,256 - $755,208
40,800 Added 41.8%
138,417 $1.85 Million
Q2 2019

Aug 14, 2019

BUY
$13.88 - $18.41 $861,948 - $1.14 Million
62,100 Added 174.85%
97,617 $1.6 Million
Q1 2019

May 15, 2019

BUY
$12.79 - $17.62 $184,176 - $253,728
14,400 Added 68.19%
35,517 $607,000
Q4 2018

Feb 14, 2019

BUY
$11.39 - $27.13 $240,522 - $572,904
21,117 New
21,117 $288,000

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $916M
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.